重组人血管内皮抑素联合NP方案治疗初诊晚期非小细胞肺癌骨转移疗效及对血清VEGF表达的影响

doi:10.11904/j.issn.1002-3070.2016.06.010

Abstract

Abstract: Objective To explore the efficacy of recombinant human endostatin(Rh-endostatin)combined with vinorelbine-cisplatin(NP)regimen for newly diagnosed patients with advanced non-small cell lung cancer(NSCLC)with bone metastases and the impact on expression of serum vascular endothelial growth factor(VEGF).Methods From January 1,2009 to February 1,2012,a total of 40 with newly diagnosed,advanced NSCLC patients with bone metastases were enrolled in this study and randomly assigned to the treatment(N=20)or control(N=20)group.The control group was only given the NP regimen chemotherapy and the treatment group was treated with Rh-endostatin combined with NP regimen.The changes in clinical effects of the two groups and serum VEGF levels were observed.Results After two cycles of systemic chemotherapy,objective response rate(ORR)and disease control rate(DCR)of the treatment group were 30.0% and 80.0% significantly higher than 5.0% and 45.0% of the control group(P＜0.05).Serum VEGF Level did not significantly change before and after treatments in the two groups(P＞0.05).Conclusion Rh-endostatin combined with NP regimen can improve the efficiency of treatment for newly diagnosed patients with advanced NSCLC with bone metastases and does not increase adverse reactions whereas no significant difference in serum VEGF Levels.

Key words: Non-small cell lung cancer, Bone metastases, Chemotherapy, Recombinant human endostatin, Vascular endothelial growth factor

CLC Number:

R734.2

ZHANG Rui,WANG Zhiyu,WANG Shuai,ZHAO Hui. Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diagnosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 527-522.

References

1 Wang J,Wang K,Xu J,et al.Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients:a meta-analysis[J].PLoS One,2013,8(11):e78070.
2 Rossi A,Chiodini P,Sun JM,et al.Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer:a systematic review and meta-analysis of individual patient data[J].Lancet Oncol,2014,15(11):1254-1262.
3 Ge W,Cao DD,Wang HM,et al.Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs:a meta-analysis[J].Asian Pac J Cancer Prev,2011,12(10):2705-2711.
4 Sun JM,Ahn JS,Lee S,et al.Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases[J].Lung Cancer,2011,71(1):89-93.
5 Lopez-Olivo MA,Shah NA,Pratt G,et al.Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease:a systematic review and meta-analysis[J].Support Care Cancer,2012,20(11):2985-2998.
6 Costelloe CM,Chuang HH,Madewell JE,et al.Cancer response criteria and bone metastases:RECIST 1.1,MDA and PERCIST[J].J Cancer,2010,1(6):80-92.
7 Hosseini H,Rajabibazl M,Ebrahimizadeh W,et al.Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF[J].Microvasc Res,2015,97(1):13-18.
8 刘黎,毛英,张匠,等.重组人血管内皮抑制素注射液联合顺铂对非小细胞肺癌患者血管内皮生长因子的影响研究[J].实用心脑肺血管病杂志,2016,24(3):127-128.
9 Folkman J.Tumor angiogenesis:therapeutic implications[J].N Engl J Med,1971,285(21):1182-1186.
10 Jain RK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J].Science,2005,307(5706):58-62.
11 Herbst RS,Ansari R,Bustin F,et al.Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy(BeTa):a double-blind,placebo-controlled,phase 3 trial[J].Lancet,2011,377(9780):1846-1854.
12 Niho S,Kunitoh H,Nokihara H,et al.Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer[J].Lung Cancer,2012,76(3):362-367.
13 Zhao X,Mei K,Cai X,et al.A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer[J].Invest New Drugs,2012,30(3):1144-1149.
14 Liu ZJ,Wang J,Wei XY,et al.Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer[J].J Cancer Res Clin Oncol,2012,138(6):927-937.
15 Sato Y.Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy[J].Cancer Sci,2011,102(7):1253-1256.
16 Han B,Xiu Q,Wang H,et al.A multicenter,randomized,double-blind,placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer[J].J Thorac Oncol,2011,6(6):1104-1109.
17 Yang F,Tang X,Riquelme E,et al.Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy[J].Cancer Res,2011,71(16):5512-5521.
18 Chen J,Yao Q,Li D,et al.Neoadjuvant rh-endostatin,docetaxel and epirubicin for breast cancer:efficacy and safety in a prospective,randomized,phase II study[J].BMC Cancer,2013,13(5):248-255.
19 Zhu Q,Zang Q,Jiang ZM,et al.Clinical application of Recombinant human endostatin in postoperative early complementary therapy on patients with Non-small cell lung cancer in Chinese Mainland[J].Asian Pac J Cancer Prev,2015,16(9):4013-4018.
20 Dahabreh IJ,Linardou H,Kosmidis P,et al.EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment:a systematic review and meta-analysis in non-small-cell lung cancer[J].Ann Oncol,2011,22(3):545-552.
21 Singh T,Kaur V,Kumar M,et al.The critical role of bisphosphonates to target bone cancer metastasis:an overview[J].J Drug Target,2015,23(1):1-15.
22 Brodowicz T,O′Byrne K,Manegold C.Bone matters in lung cancer[J].Ann Oncol,2012,23(9):2215-2222.
23 Song Z,Zhang Y.Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases[J].Med Oncol,2014,31(4):898.
24 Yuen T,Stachnik A,Iqbal J,et al.Bisphosphonates inactivate human EGFRs to exert antitumor actions[J].Proc Natl Acad Sci U S A,2014,111(50):17989-17994.

[1]	LIANG Hong, LI Qi, WANG Yaoxian, JIN Hong, WANG Tong, WANG Yanan, DUAN Yani, SONG Min. Interrupted time series trial for prevention of cardiovascular toxicity induced by chemotherapy in cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 134-138.
[2]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[3]	QIN Lanqun, ZOU Zhengyun. Progress in chemotherapy for malignant melanoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 167-172.
[4]	CHANG Xiaoxia, SONG Bingbing, LIU Jiaren. Research progress in phytochemicals for increasing sensitivity of tumor cells to chemotherapies [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 67-72.
[5]	LI Wanzhen, YIN Jun, LI Ping, LIN Xiaohui, ZHANG Guoqian, ZHANG Shuxu. The expression and role of miR-17 in radioresistant cells of non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 391-397.
[6]	CAI Jing, HOU Yue. The expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 415-419.
[7]	JIANG Liangliang, WANG Jing. Progress in diagnosis and treatment of distant metastasis of epithelial ovarian cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 480-482.
[8]	CUI Xiaoyan,TU Qing,GAN Jianhui. Comparison between nalbuphine and oxycodone applied for patient controlled analgesia on postoperative immunological factor levels in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 309-314.
[9]	ZHANG Li,FANG Kewei,YUE Xi,WANG Hong,YANG Hanfeng,XU Xiaoxue. Research progress of cryoablation for bone metastases [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 353-356.
[10]	LEI Junhua, XU Guanhua, ZENG Jiangzheng, HUANG Fen, HE Zhihui, LU Yanda. Research on JAK3/STAT3 mechanism of non-small cell lung cancer NCI-H1975 cells treated with cryptotanshinone combined with cisplatin [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 198-202.
[11]	ZHANG Ting, JIA Di, YANG Dan. Progress in biological treatment of osteosarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 254-257.
[12]	ZHAI Keke, GAO Yuanyuan, FENG Xiao, XU Jingwen, GONG Yufang, MENG Qingwei. Analysis of first-line NSCLC chemotherapy in the phase Ⅳ patients with distant metastasis and first diagnosis after postoperative adjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 107-111.
[13]	DU Yesheng, HU Songliu, XU Xiangying. Study of oligodendrocyte metastasis in non-small cell lung cancer by stereotactic radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 154-158.
[14]	YANG Wenjuan, YU Jing, HUANG Zhao, ZHANG Junhong, XIE Conghua. Correlation between the decline of severe granulocyte in the early stage of chemotherapy and the prognosis of small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 19-24.
[15]	SUN Mingliang, XU Jianyu, XU Xiangying. Stereotactic radiotherapy for early stage of non - small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 53-56.

Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diagnosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments